<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211144</url>
  </required_header>
  <id_info>
    <org_study_id>1175.21</org_study_id>
    <nct_id>NCT02211144</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects</brief_title>
  <official_title>Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally (Total Daily Dose 90, 120, 150 or 180 mg) to Healthy Human Subjects for 14 Days. A Placebo-controlled, Dose Escalation Study Double Blinded at Each Dose Level</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the safety and pharmacokinetics of BIRB 796 BS tablets administered as
      multiple daily doses at various dose levels
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <primary_completion_date type="Actual">November 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs (pulse rate, systolic and diastolic blood pressure)</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically relevant changes in laboratory parameters</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinical relevant findings in electrocardiogram (ECG)</measure>
    <time_frame>up to day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical assessment of tolerability on a 4-point scale</measure>
    <time_frame>day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration during steady state dosing interval (Cmax,ss)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration versus time curve at different time points (AUC)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the maximum plasma concentration at steady state (tmax,ss)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average steady state plasma concentration (Css)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total apparent oral clearance of drug from plasma after oral administration (CL/F )</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution based on terminal elimination phase, divided by F (bioavailability factor) (Vz/F)</measure>
    <time_frame>up to day 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning trough plasma concentration prior day 14</measure>
    <time_frame>on day 2, 3, 5, 7, 9, 13 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIRB 796 BS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in escalating doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 796 BS</intervention_name>
    <arm_group_label>BIRB 796 BS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>BIRB 796 BS</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects as determined by results of screening

          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and
             local legislation

          -  Female subjects who were not lactating and not of child bearing potential as defined
             by surgically sterile or post menopausal (no periods for at least 12 months and
             elevated follicle stimulating hormone (FSH) with low estradiol while on no estrogen
             supplementation). Females were to use barrier contraception (e.g. condoms) prior to
             administration of study medication, during the study and at least one month after
             release from the study. Women must have had negative blood pregnancy tests

          -  Age ≥ 18 and ≤ 60 years

          -  Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2

          -  Able to communicate well with the investigator and to comply with study requirements

          -  Laboratory values within a clinically defined reference range

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate, and
             electrocardiogram) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic
             or hormonal disorders

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  History of vasculitis (past history of fever, malaise, myalgias, rash, etc.)

          -  Intake of drugs with a long half-life (&gt; 24 hours) (&lt; 1 month prior to administration
             or during the trial)

          -  Use of any drugs, which might influence the results of the trial, (&lt; 10 days prior to
             administration or during the trial)

          -  Participation in another trial with an investigational drug (&lt; 1 months prior to
             administration (at least 10 times the relevant elimination half-life) or during the
             trial)

          -  Having had prescription medication 2 weeks prior to study drug administration or over
             the counter medication 1 week prior to study drug administration (at least 10 times
             the relevant elimination half-life)

          -  Smoker

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Use of methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks,
             chocolate, etc.), grapefruit or grapefruit juice, alcohol, green tea, or tobacco &lt; 5
             days prior to administration of study drug

          -  Blood donation or loss &gt; 400 mL (&lt; 1 month prior to administration or during the
             trial)

          -  Excessive physical activities (&lt; 5 days prior to administration or during the trial)

          -  Following specific laboratory findings: white blood cell count, C-reactive protein,
             gamma-glutamyl-transferase, aspartate transaminase, alanine transaminase, or glutamate
             dehydrogenase above the normal range; any erythrocytes or &gt; 15 mg/dl protein on urine
             dipstick if not menstruating

          -  Any EKG value outside of the reference range of clinical relevance including, but not
             limited to QTcB &gt; 480 ms or QRS interval &gt; 110 ms

          -  History of any familial bleeding disorder

          -  Inability to comply with dietary regimen of study centre

          -  Inability to comply with investigator's instructions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

